The Liver Core Center will provide technical and intellectual support and expertise for the liver-related research projects in the Schools of Medicine and Pharmacy of the University of California, San Francisco. It further will provide limited funds for pilot and feasibility studies. The Center will be based on the combined facilities and resources of the Schools of Medicine and Pharmacy, the Moffitt-University Hospital, the San Francisco Veterans Administration Hospital and the San Francisco General Hospital. The overall goals of the Center are to enhance the quality and productivity of individually funded research projects; to foster interdisciplinary communication and collaboration between investigators of different departments and schools; to stimulate new interdisciplinary research projects; to provide technical and procedural resources not available to individual research projects; to optimize the use of available technical and intellectual resources. The main emphasis of the Core Center will be on new and novel concepts and approaches to liver function and structure, both in the physiological state and in a variety of diseases, including drug-induced liver injury. The Core Center will be under the direction of a Program Director, two Deputy Directors, an Executive Committee and an Advisory Board, responsible to the Dean of the School of Medicine.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK026743-10
Application #
3101986
Study Section
(SRC)
Project Start
1985-07-01
Project End
1990-11-30
Budget Start
1989-07-01
Budget End
1990-11-30
Support Year
10
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Méndez-Lagares, Gema; Lu, Ding; Chen, Connie et al. (2018) Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. J Immunol 200:1124-1132
Cullaro, Giuseppe; Sarkar, Monika; Lai, Jennifer C (2018) Sex-based disparities in delisting for being ""too sick"" for liver transplantation. Am J Transplant 18:1214-1219
Liu, Xianqiong; Song, Xinhua; Zhang, Jie et al. (2018) Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma. Cancer Med 7:6170-6181
Mehta, Neil; Guy, Jennifer; Frenette, Catherine T et al. (2018) Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol 16:955-964
Lee, Briton; Holt, Edward W; Wong, Robert J et al. (2018) Race/ethnicity is an independent risk factor for autoimmune hepatitis among the San Francisco underserved. Autoimmunity 51:258-264
Roberts, Daniel E; Kakar, Sanjay; Mehta, Neil et al. (2018) A Point-based Histologic Scoring System for Hepatocellular Carcinoma Can Stratify Risk of Posttransplant Tumor Recurrence. Am J Surg Pathol 42:855-865
Sarkar, Monika; Bramham, Kate; Moritz, Michael J et al. (2018) Reproductive health in women following abdominal organ transplant. Am J Transplant 18:1068-1076
Perito, Emily R; Phelps, Andrew; Vase, Tabitha et al. (2018) Subclinical Atherosclerosis in Pediatric Liver Transplant Recipients: Carotid and Aorta Intima-Media Thickness and Their Predictors. J Pediatr 193:119-127.e1
Schaub, Johanna R; Huppert, Kari A; Kurial, Simone N T et al. (2018) De novo formation of the biliary system by TGF?-mediated hepatocyte transdifferentiation. Nature 557:247-251
Wang, Jingxiao; Dong, Mingjie; Xu, Zhong et al. (2018) Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene 37:3229-3242

Showing the most recent 10 out of 1119 publications